Rolf Wachter1, Daniel Viriato2, Sven Klebs3, Stefanie S Grunow4, Matthias Schindler5, Johanna Engelhard4, Catia C Proenca6, Frederico Calado7, Raymond Schlienger8, Markus Dworak9, Bogdan Balas10, Sara Bruce Wirta7. 1. a Clinic and Policlinic for Cardiology , University Hospital Leipzig , Leipzig , Germany. 2. b Global Health Economics and Outcomes Research , Novartis Pharma AG , Basel , Switzerland. 3. c Health Economics and Outcomes Research, Cardio Metabolic , Novartis Pharma GmbH , Nuremberg , Germany. 4. d Real World Insights , QuintilesIMS Germany (IMS HEALTH GmbH & Co. OHG) , Frankfurt , Germany. 5. e Real World Insights , QuintilesIMS Switzerland , Basel , Switzerland. 6. f Wellmera AG , Basel , Switzerland. 7. g Real World Evidence , Cardio Metabolic, Novartis Sweden AB , Stockholm , Sweden. 8. h Quality and Safety Epidemiology , Cardio Metabolic, Novartis Pharma AG , Basel , Switzerland. 9. i Clinical Research , Cardio Metabolic, Novartis Pharma GmbH , Nuremberg , Germany. 10. j Global Medical Affairs Cardio Metabolic , Novartis Pharma AG , Basel , Switzerland.
Abstract
OBJECTIVES: This study aimed to provide early insights into sacubitril/valsartan (sac/val) prescription patterns and the demographic and clinical characteristics of patients prescribed sac/val in primary care and cardiology settings in Germany. METHODS: The study used electronic medical records from the German IMS® Disease Analyzer database. Patients with ≥1 prescription for sac/val during 1 January-31 December 2016 (n = 1643) were identified and followed up for ≤12 months from first prescription. Patients with ≥1 heart failure (HF) diagnosis during the study period, ≥1 additional HF diagnosis in the full history of the database, and ≥1 prescription for an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and a β-blocker during the study period, without a prescription for sac/val (n = 25,264), were included as a reference cohort. Changes in clinical parameters in the 12 months before and after sac/val initiation were investigated and compared with those from the PARADIGM-HF study. RESULTS: The characteristics of patients prescribed sac/val more closely resembled those of patients enrolled in PARADIGM-HF (e.g. younger age, higher proportion of men than women, lower systolic blood pressure) than patients in the reference cohort. Most patients were initiated on the lowest dose of sac/val irrespective of clinical setting. Significant decreases (p < 0.001) in NT-proBNP and glycated haemoglobin levels were observed following sac/val initiation. CONCLUSIONS: Patients prescribed sac/val had similar baseline demographics and clinical characteristics to those from PARADIGM-HF, and most patients were initiated on the lowest dose. Changes in clinical parameters before and after initiation mirrored findings from the PARADIGM-HF study.
OBJECTIVES: This study aimed to provide early insights into sacubitril/valsartan (sac/val) prescription patterns and the demographic and clinical characteristics of patients prescribed sac/val in primary care and cardiology settings in Germany. METHODS: The study used electronic medical records from the German IMS® Disease Analyzer database. Patients with ≥1 prescription for sac/val during 1 January-31 December 2016 (n = 1643) were identified and followed up for ≤12 months from first prescription. Patients with ≥1 heart failure (HF) diagnosis during the study period, ≥1 additional HF diagnosis in the full history of the database, and ≥1 prescription for an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and a β-blocker during the study period, without a prescription for sac/val (n = 25,264), were included as a reference cohort. Changes in clinical parameters in the 12 months before and after sac/val initiation were investigated and compared with those from the PARADIGM-HF study. RESULTS: The characteristics of patients prescribed sac/val more closely resembled those of patients enrolled in PARADIGM-HF (e.g. younger age, higher proportion of men than women, lower systolic blood pressure) than patients in the reference cohort. Most patients were initiated on the lowest dose of sac/val irrespective of clinical setting. Significant decreases (p < 0.001) in NT-proBNP and glycated haemoglobin levels were observed following sac/val initiation. CONCLUSIONS:Patients prescribed sac/val had similar baseline demographics and clinical characteristics to those from PARADIGM-HF, and most patients were initiated on the lowest dose. Changes in clinical parameters before and after initiation mirrored findings from the PARADIGM-HF study.
Entities:
Keywords:
Electronic medical records; PARADIGM-HF; heart failure with reduced ejection fraction; patient characteristics; sacubitril/valsartan
Authors: Vyacheslav A Korshunov; Breandan Quinn; Abrar Faiyaz; Rifat Ahmed; Mark P Sowden; Marvin M Doyley; Bradford C Berk Journal: Br J Pharmacol Date: 2019-06-24 Impact factor: 8.739
Authors: Rolf Wachter; Ana F Fonseca; Bogdan Balas; Elisabeth Kap; Johanna Engelhard; Raymond Schlienger; Sven Klebs; Sara Bruce Wirta; Karel Kostev Journal: Eur J Heart Fail Date: 2019-04-11 Impact factor: 15.534
Authors: Rolf Wachter; Sven Klebs; Bogdan Balas; Elisabeth Kap; Johanna Engelhard; Raymond Schlienger; Sara Bruce Wirta; Ana Filipa Fonseca Journal: ESC Heart Fail Date: 2020-07-31